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OBSERVATIONS
Pioglitazone-
Induced Acute
Rhabdomyolysis
P
ioglitazone, a peroxisome prolifera-
tor–activatedreceptoragonist,isa
relatively new oral antidiabetes
agent. It has been shown to decrease in-
sulin resistance in patients with type 2
diabetes, resulting in lowered blood glu-
cose concentrations and A1C values. It
can be used alone or in combination with
metformin or a sulfonylurea. The adverse
effects of pioglitazone include weight
gain, headache, and edema.
Wereporthereacaseofapatientwho
developed severe acute rhabdomyolysis
after receiving pioglitazone. A 52-year-
old man had a 2-year history of type 2
diabetes that was treated with gliclazide
(60 mg/day). Six weeks after addition for
pioglitazone (15 mg/day), the patient was
admittedtohospitalfor4daysformyalgia
and severe muscle weakness.
He had no recent viral illness or other
complaints. He denied any change from
his normal level of activity. No alcohol
ingestion, illicit drugs, unprescribed
medication use, or trauma was present.
A physical examination revealed se-
vere proximal muscle weakness and ten-
derness affecting all four limbs.
Laboratory tests showed marked in-
creases in the serum creatinine phos-
phokinase (9,851 IU/l [normal limit 150
IU/l]), serum myoglobin, and aspartate
aminotransferase (98 IU/l) levels. His cre-
atinine serum level was normal at 60
mol/l. There were no signs of severe hy-
perglycemia, diabetic ketoacidosis, hypo-
kalemia, or hypophosphatemia.
Autoantibody screening and viral se-
rologies were negative. Thyroid function
was normal. Electromyography studies
and a muscle biopsy were not considered
to be warranted at that time. Drug-
induced rhabdomyolysis was suspected,
pioglitazone was stopped, and the patient
underwent hydration and bicarbonate
therapy.
The patient’s serum creatinine phos-
phokinase level declined to 752 IU/l on
day ﬁve after admission and returned to
baselinewithin4weeksofdischargefrom
the hospital. His muscle symptoms had
also improved. His glycemia was well
controlled with gliclazide and acarbose.
According to the Naranjo probability
scale, pioglitazone-induced rhabdomyol-
ysis was probable (1). This diagnosis is
based on the exclusion of potential med-
icalcausessuchashypothyroidism,infec-
tion, muscle trauma, alcoholism, the
patient’s drug exposure, and the resolu-
tion of signs and symptoms when piogli-
tazone was withdrawn.
In our review of the literature and ac-
cording to data from a MEDLINE search,
previous case reports of elevated serum
creatinine phosphokinase, myopathy, or
rhabdomyolysis have been identiﬁed in
patients taking rosiglitazone or troglita-
zone (2,3). Potential risk factors identi-
ﬁed in these cases included concomitant
therapy with ﬁbrate, alcohol abuse, and
asymptomatic mild creatinine phos-
phokinase elevation prior to initiating
therapy.
A recent study identiﬁed no signiﬁ-
cant differences in rates of myopathic
events in type 2 diabetic patients taking
thiazolidinediones (rosiglitazone or pio-
glitazone) compared with those taking
other antidiabetic agents (4). Further-
more,concomitantuseofstatinsandthia-
zolidinediones was not associated with
increased risk of myopathic events be-
yond that conferred by statins alone. Al-
though no case reports of pioglitazone-
induced severe myopathy and
rhabdomyolysis were identiﬁed in our
search,isolatedminorelevationsinserum
creatinine phosphokinase levels or mus-
clepainwerereportedasanadverseeffect
of this drug (5). Clinicians should be vig-
ilant of this side effect, and a monitoring
of serum creatinine phosphokinase levels
in patients on pioglitazone monotherapy
who developed myalgia seems to be
reasonable.
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